Jubilant Pharmova Limited Share Price & Analysis
₹1,007.8▼ -1.57%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹1,007.8
-1.57%
Open
₹—
High
₹1,025.05
Low
₹1,003.2
Close
₹1,007.8
52W High
₹1,250
52W Low
₹784
Volume
71K
Lot Size
1
Sector
Healthcare
Market Cap
₹16K Cr
Face Value
₹1
Mid CapNIFTY 500
Price Chart
Fundamentals
P/E
37.3
Sector P/E
54.4
P/B
2.34
EPS
₹25.08
ROE
6.55%
ROCE
8.99%
D/E Ratio
0.51
Div Yield
0.49%
Book Value
₹445
+
Strengths
- ✓Attractively valued vs sector (P/E 37.3x vs industry 54.4x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
JUBLPHARMA · as of Mar 2026
Promoters50.67%
FII17.23%▲0.27
DII7.05%▲0.06
Public24.48%▼0.34
Others0.56%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.67% | 50.67% | 50.67% | 50.67% | 50.67% | 50.67% |
| FII | 20.29% | 19.06% | 19.50% | 17.94% | 16.96% | 17.23% |
| DII | 2.89% | 3.77% | 4.06% | 5.66% | 6.99% | 7.05% |
| Public | 25.56% | 25.91% | 25.18% | 25.17% | 24.82% | 24.48% |
| Others | 0.58% | 0.58% | 0.58% | 0.56% | 0.56% | 0.56% |
Corporate Events
Dividend - Rs 5 Per Share
Dividend23 Jul 2026
Dividend - Rs 5 Per Share
Dividend24 Jul 2025
Dividend - Rs 5 Per Share
Dividend1 Aug 2024
Dividend - Rs 5 Per Share
Dividend9 Aug 2023
Latest News
All news →Jubilant Foodworks grants stock options to employees
*Jubilant Foodworks grants stock options to employees under its ESOP scheme.* The move is part of employee retention and incentive strategy. No immediate financial impact expected as it's a routine corporate action. Options granted subject to vesting conditions. 📊 *STOCKS:* JUBLFOOD | 🏢 *SECTOR:* Consumer Discretionary | #LOWIMPACT #StockOptions
NSE Filing15 Jul
Jubilant Foodworks opens special window for share transfer re-lodgement
Jubilant Foodworks has announced a special window for re-lodgement of transfer deeds for physical shares. This facilitates investors who faced issues earlier in transferring ownership. The move aims to ease shareholder operations amid ongoing digitization trends. 📊 *STOCKS:* JUBLFOOD | 🏢 *SECTOR:* Food Services | #LOWIMPACT #ShareTransfer
NSE Filing13 Jul
Jubilant Pharmova issues general corporate updates
*Jubilant Pharmova issues general corporate updates.* The company filed routine disclosures with the NSE, containing no major financial or strategic announcements. These updates do not indicate any immediate change in business operations or financial outlook. 📊 *STOCKS:* JUBLPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
NSE Filing19 Jun
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.3K Cr ▲7.9% | ₹2.1K Cr ▲7.9% | ₹2.0K Cr ▲3.4% | ₹1.9K Cr ▼1.5% | ₹1.9K Cr ▲5.9% | ₹1.8K Cr ▲4.0% | ₹1.8K Cr ▲1.2% | ₹1.7K Cr |
| Op. Profit | ₹339 Cr ▲17.3% | ₹289 Cr ▼15.2% | ₹341 Cr ▲17.6% | ₹290 Cr ▼15.9% | ₹345 Cr ▲20.2% | ₹287 Cr ▼0.7% | ₹289 Cr ▲14.7% | ₹252 Cr |
| OPM | 15.0% ▲7.1% | 14.0% ▼17.6% | 17.0% ▲13.3% | 15.0% ▼16.7% | 18.0% ▲12.5% | 16.0% ▼5.9% | 17.0% ▲13.3% | 15.0% |
| Net Profit | ₹119 Cr ▲112.5% | ₹56 Cr ▼53.3% | ₹120 Cr ▲17.6% | ₹102 Cr ▼32.5% | ₹151 Cr ▲49.5% | ₹101 Cr ▼1.0% | ₹102 Cr ▼78.8% | ₹482 Cr |
| EPS (₹) | 7.5 ▲113.7% | 3.51 ▼53.5% | 7.55 ▲16.9% | 6.46 ▼33.0% | 9.64 ▲52.3% | 6.33 ▼1.9% | 6.45 ▼78.7% | 30.26 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8.3K Cr ▲14.5% | ₹7.2K Cr ▲7.9% | ₹6.7K Cr ▲6.7% | ₹6.3K Cr ▲2.5% | ₹6.1K Cr ▲0.5% | ₹6.1K Cr ▲2.1% | ₹6.0K Cr ▼34.4% | ₹9.1K Cr ▲21.2% | ₹7.5K Cr ▲28.3% | ₹5.9K Cr |
| Expenses | ₹7.0K Cr ▲15.8% | ₹6.1K Cr ▲4.5% | ₹5.8K Cr ▲5.4% | ₹5.5K Cr ▲10.5% | ₹5.0K Cr ▲6.1% | ₹4.7K Cr ▲6.0% | ₹4.4K Cr ▼39.9% | ₹7.4K Cr ▲22.9% | ₹6.0K Cr ▲32.9% | ₹4.5K Cr |
| Op. Profit | ₹1.3K Cr ▲7.4% | ₹1.2K Cr ▲30.2% | ₹901 Cr ▲15.7% | ₹779 Cr ▼32.3% | ₹1.1K Cr ▼18.0% | ₹1.4K Cr ▼9.4% | ₹1.5K Cr ▼11.2% | ₹1.7K Cr ▲14.6% | ₹1.5K Cr ▲12.6% | ₹1.4K Cr |
| OPM | 15.0% ▼6.3% | 16.0% ▲23.1% | 13.0% ▲8.3% | 12.0% ▼36.8% | 19.0% ▼17.4% | 23.0% ▼11.5% | 26.0% ▲36.8% | 19.0% ▼5.0% | 20.0% ▼13.0% | 23.0% |
| Other Income | ₹7 Cr ▼98.3% | ₹416 Cr ▲647.4% | ₹-76 Cr ▼744.4% | ₹-9 Cr ▼212.5% | ₹8 Cr ▼97.0% | ₹263 Cr ▲16.9% | ₹225 Cr ▲190.4% | ₹-249 Cr ▼791.7% | ₹36 Cr ▲89.5% | ₹19 Cr |
| Interest | ₹212 Cr ▼11.7% | ₹240 Cr ▼11.8% | ₹272 Cr ▲44.7% | ₹188 Cr ▲29.7% | ₹145 Cr ▼21.2% | ₹184 Cr ▼8.0% | ₹200 Cr ▼9.1% | ₹220 Cr ▼22.5% | ₹284 Cr ▼16.7% | ₹341 Cr |
| Depreciation | ₹440 Cr ▲19.2% | ₹369 Cr ▼3.4% | ₹382 Cr ▼31.0% | ₹554 Cr ▲45.0% | ₹382 Cr ▲9.5% | ₹349 Cr ▲2.6% | ₹340 Cr ▼8.4% | ₹371 Cr ▼10.6% | ₹415 Cr ▲42.6% | ₹291 Cr |
| PBT | ₹614 Cr ▼37.4% | ₹981 Cr ▲477.1% | ₹170 Cr ▲507.1% | ₹28 Cr ▼95.6% | ₹630 Cr ▼44.4% | ₹1.1K Cr ▼8.1% | ₹1.2K Cr ▲36.4% | ₹904 Cr ▲5.2% | ₹859 Cr ▲16.4% | ₹738 Cr |
| Tax % | 35.0% ▲133.3% | 15.0% ▼73.7% | 57.0% ▼82.9% | 333.0% ▲879.4% | 34.0% ▲30.8% | 26.0% ▼3.7% | 27.0% ▼25.0% | 36.0% ▲38.5% | 26.0% ▲18.2% | 22.0% |
| Net Profit | ₹398 Cr ▼52.4% | ₹836 Cr ▲1045.2% | ₹73 Cr ▲212.3% | ₹-65 Cr ▼115.7% | ₹413 Cr ▼50.6% | ₹836 Cr ▼6.9% | ₹898 Cr ▲55.6% | ₹577 Cr ▼9.0% | ₹634 Cr ▲10.3% | ₹575 Cr |
| EPS (₹) | 25.02 ▼52.5% | 52.69 ▲988.6% | 4.84 ▲226.4% | -3.83 ▼114.7% | 25.98 ▼50.5% | 52.47 ▼7.0% | 56.39 ▲56.4% | 36.06 ▼10.6% | 40.35 ▲11.6% | 36.14 |
| Div Payout | 20.0% ▲122.2% | 9.0% ▼91.2% | 102.0% ▲178.5% | -130.0% ▼784.2% | 19.0% ▲90.0% | 10.0% ▲11.1% | 9.0% ▼25.0% | 12.0% ▲71.4% | 7.0% ▼12.5% | 8.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr |
| Reserves | ₹7.1K Cr ▲13.4% | ₹6.2K Cr ▲15.2% | ₹5.4K Cr ▲0.7% | ₹5.4K Cr ▲1.5% | ₹5.3K Cr ▲12.2% | ₹4.7K Cr ▼15.4% | ₹5.6K Cr ▲16.6% | ₹4.8K Cr ▲17.7% | ₹4.1K Cr ▲19.0% | ₹3.4K Cr |
| Borrowings | ₹3.6K Cr ▲32.4% | ₹2.7K Cr ▼25.5% | ₹3.7K Cr ▼0.4% | ₹3.7K Cr ▲15.2% | ₹3.2K Cr ▲12.8% | ₹2.8K Cr ▼41.1% | ₹4.8K Cr ▼0.7% | ₹4.8K Cr ▲39.5% | ₹3.5K Cr ▼14.2% | ₹4.0K Cr |
| Other Liabilities | ₹4.8K Cr ▲33.8% | ₹3.6K Cr ▲60.6% | ₹2.2K Cr ▲20.9% | ₹1.9K Cr ▲40.5% | ₹1.3K Cr ▲10.7% | ₹1.2K Cr ▼37.2% | ₹1.9K Cr ▲13.7% | ₹1.7K Cr ▼12.2% | ₹1.9K Cr ▲34.2% | ₹1.4K Cr |
| Total Liabilities | ₹15.5K Cr ▲23.4% | ₹12.6K Cr ▲11.0% | ₹11.3K Cr ▲3.7% | ₹10.9K Cr ▲11.2% | ₹9.8K Cr ▲12.2% | ₹8.8K Cr ▼28.8% | ₹12.3K Cr ▲8.8% | ₹11.3K Cr ▲19.7% | ₹9.5K Cr ▲6.3% | ₹8.9K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹8.0K Cr ▲55.4% | ₹5.2K Cr ▲1.7% | ₹5.1K Cr ▼1.8% | ₹5.2K Cr ▲6.4% | ₹4.9K Cr ▲5.7% | ₹4.6K Cr ▼27.3% | ₹6.3K Cr ▲12.3% | ₹5.6K Cr ▲4.6% | ₹5.4K Cr ▲5.8% | ₹5.1K Cr |
| CWIP | ₹3.0K Cr ▼18.4% | ₹3.6K Cr ▲72.6% | ₹2.1K Cr ▲34.6% | ₹1.6K Cr ▲43.3% | ₹1.1K Cr ▲21.5% | ₹897 Cr ▲16.8% | ₹768 Cr ▼14.8% | ₹901 Cr ▲34.3% | ₹671 Cr ▼1.9% | ₹684 Cr |
| Investments | ₹61 Cr ▲38.6% | ₹44 Cr ▲4.8% | ₹42 Cr ▼83.6% | ₹256 Cr ▲7.1% | ₹239 Cr ▼0.8% | ₹241 Cr ▲249.3% | ₹69 Cr ▼40.0% | ₹115 Cr ▼7.3% | ₹124 Cr ▲20.4% | ₹103 Cr |
| Other Assets | ₹4.5K Cr ▲19.3% | ₹3.7K Cr ▼8.9% | ₹4.1K Cr ▲4.4% | ₹3.9K Cr ▲8.2% | ₹3.6K Cr ▲20.4% | ₹3.0K Cr ▼41.2% | ₹5.1K Cr ▲10.3% | ₹4.7K Cr ▲42.7% | ₹3.3K Cr ▲8.5% | ₹3.0K Cr |
| Total Assets | ₹15.5K Cr ▲23.4% | ₹12.6K Cr ▲11.0% | ₹11.3K Cr ▲3.7% | ₹10.9K Cr ▲11.2% | ₹9.8K Cr ▲12.2% | ₹8.8K Cr ▼28.8% | ₹12.3K Cr ▲8.8% | ₹11.3K Cr ▲19.7% | ₹9.5K Cr ▲6.3% | ₹8.9K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.2K Cr ▲14.5% | ₹1.1K Cr ▲10.4% | ₹971 Cr ▲46.9% | ₹661 Cr ▼21.1% | ₹838 Cr ▼53.0% | ₹1.8K Cr ▲15.6% | ₹1.5K Cr ▲37.5% | ₹1.1K Cr ▼13.9% | ₹1.3K Cr ▲2.8% | ₹1.3K Cr |
| Investing CF | ₹-1.3K Cr ▼346.1% | ₹512 Cr ▲185.9% | ₹-596 Cr ▼25.7% | ₹-474 Cr ▼46.7% | ₹-323 Cr ▲55.6% | ₹-727 Cr ▼172.3% | ₹-267 Cr ▲73.8% | ₹-1.0K Cr ▼65.8% | ₹-614 Cr ▼32.0% | ₹-465 Cr |
| Financing CF | ₹95 Cr ▲106.5% | ₹-1.5K Cr ▼236.3% | ₹-432 Cr ▼175.2% | ₹-157 Cr ▼375.8% | ₹-33 Cr ▲98.1% | ₹-1.7K Cr ▼62.8% | ₹-1.1K Cr ▼259.8% | ₹657 Cr ▲172.9% | ₹-901 Cr ▼31.3% | ₹-686 Cr |
| Net Cash Flow | ₹62 Cr ▼53.0% | ₹132 Cr ▲327.6% | ₹-58 Cr ▼293.3% | ₹30 Cr ▼93.8% | ₹482 Cr ▲173.9% | ₹-652 Cr ▼389.8% | ₹225 Cr ▼70.4% | ₹761 Cr ▲459.0% | ₹-212 Cr ▼281.2% | ₹117 Cr |
| Free Cash Flow | ₹-120 Cr ▼215.8% | ₹-38 Cr ▼145.8% | ₹83 Cr ▲161.5% | ₹-135 Cr ▼156.0% | ₹241 Cr ▼81.0% | ₹1.3K Cr ▲30.3% | ₹975 Cr ▲106.1% | ₹473 Cr ▼42.2% | ₹819 Cr ▲1.6% | ₹806 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47d ▲4.4% | 45d ▼10.0% | 50d ▼10.7% | 56d ▲1.8% | 55d ▲12.2% | 49d ▼38.0% | 79d ▲54.9% | 51d ▼7.3% | 55d ▼12.7% | 63d |
| Inventory Days | 170d ▼4.5% | 178d ▼19.1% | 220d ▼17.9% | 268d ▼13.0% | 308d ▲14.9% | 268d ▼42.1% | 463d ▲215.0% | 147d ▼16.9% | 177d ▼20.6% | 223d |
| Days Payable | 170d ▲7.6% | 158d ▲8.2% | 146d ▼8.8% | 160d ▲15.1% | 139d ▲12.1% | 124d ▼54.6% | 273d ▲157.5% | 106d ▼26.9% | 145d ▲5.8% | 137d |
| Cash Conv. Cycle | 47d ▼27.7% | 65d ▼47.6% | 124d ▼24.8% | 165d ▼26.3% | 224d ▲15.5% | 194d ▼27.6% | 268d ▲191.3% | 92d ▲5.7% | 87d ▼41.6% | 149d |
| Working Capital Days | 13d ▼18.8% | 16d ▼71.4% | 56d ▼1.8% | 57d ▲1.8% | 56d ▼24.3% | 74d ▲19.4% | 62d ▲37.8% | 45d ▲0.0% | 45d ▼10.0% | 50d |
| ROCE | 9.0% ▼10.0% | 10.0% ▲42.9% | 7.0% ▲133.3% | 3.0% ▼70.0% | 10.0% ▼16.7% | 12.0% ▼20.0% | 15.0% ▼6.3% | 16.0% ▲6.7% | 15.0% ▲0.0% | 15.0% |
Source: Screener.in · Lower days = better efficiency
About Jubilant Pharmova Limited
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Jubilant Pharmova Limited share price today?▾
Jubilant Pharmova Limited (JUBLPHARMA) is currently trading at ₹1,007.8 on NSE, down 1.57% as of the last market session. Prices update daily after market close on MarketNetra.
Is Jubilant Pharmova Limited available in F&O (Futures & Options)?▾
Yes, Jubilant Pharmova Limited (JUBLPHARMA) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Jubilant Pharmova Limited 52-week high and low?▾
Jubilant Pharmova Limited's 52-week high is ₹1,250 and the 52-week low is ₹784. The current price of ₹1,007.8 is 19.4% below the 52W high.
What is Jubilant Pharmova Limited P/E ratio?▾
Jubilant Pharmova Limited's current P/E ratio is 37.3. This indicates the market is paying ₹37.3 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Jubilant Pharmova Limited options?▾
Jubilant Pharmova Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade JUBLPHARMA options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.